Chronic hepatitis C infection is associated with changes of glucose metabolism end increased frequency of impaired glucose tolerance. This might be a additional risk factor for disease and fibrosis progression. The study aims to evaluate whether a therapy with direct-acting antiviral agents leading to a sustained virologic response directly impacts parameters reflecting glucose metabolism and fibrosis.
Chronic hepatitis C infection is associated with changes of glucose metabolism end increased frequency of impaired glucose tolerance. It is well known that metabolic factors play an important role in fibrosis progression and steatohepatitis for example in non-alcoholic steatohepatitis (NASH). Accordingly changes in glucose metabolism in patients with chronic hepatitis C might directly impact disease and fibrosis progression. The study aims to evaluate whether a therapy with direct-acting antiviral agents leading to a sustained virologic response directly impacts parameters reflecting glucose metabolism and fibrosis. Follow-up examinations will determine the long-term metabolic changes of successful elimination of the virus by antiviral treatment.
Study Type
OBSERVATIONAL
Enrollment
46
Patient characteristics, lab values reflecting glucose metabolism and non-invasive fibrosis tests are documented at baseline, during therapy and up to one year after end of treatment.
Klinikum der J. W. Goethe-Universität
Frankfurt am Main, Germany
Rate of patients with changes in glucose metabolism measured by fasting glucose
rate of patients with normal fasting glucose (\<100mg/dl), prediabetes (glucose 100-125mg/d) and diabetes (\>126mg/dl)
Time frame: From baseline up to one year after end of treatment
Rate of patients with changes in glucose metabolism measured by Homeostasis Model Assessment-index (HOMA)
Homeostasis Model Assessment-index (HOMA) measures insulin resistance: 1. \<2,0 insulin resistance unlikely 2. 2,0 - 2,5 insulin resistance possible 3. 2,5 - 5,0 insulin resitance likely 4. \>5,0 proven insulin resitance
Time frame: From baseline up to one year after end of treatment
Rate of patients with changes in glucose metabolism measured by HbA1c
rate of patients with normal HbA1c (\>6% Hb), prediabetes (6-6.4% Hb) and diabetes (\>6.5% Hb)
Time frame: From baseline up to one year after end of treatment
Liver fibrosis 1
Evaluation of changes of parameters reflecting liver fibrosis: Fibroscan
Time frame: From baseline up to one year after end of treatment
Liver fibrosis 2
Evaluation of changes of parameters reflecting liver fibrosis: ARFI
Time frame: From baseline up to one year after end of treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.